Sunday, September 14, 2025 9/14/2025

Epitranscriptomics in human obesity and type 2 diabetes

Award Number: RC2DK139552
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2024
PERIOD OF PERFORMANCE END DATE: 06/30/2029

Group Awards By:

View Award Description

Epitranscriptomics in human obesity and type 2 diabetes - PROJECT SUMMARY Dysfunction of multiple metabolic cells contribute to the pathophysiology of the two major pathological states, obesity and type 2 diabetes, which have a huge economic burden worldwide. Identifying the etiology of the two linked pathological states continues to be an area of intense research with a focus on identifying new regulatory pathways within tissues that impact metabolic function and cause dysfunction. There is a continuing need to develop a systems biology framework that integrates real patient data to inform signaling within cells and crosstalk between tissues to enable identification of potential new targets for effective therapy. An emerging area of significance in human obesity and type 2 diabetes (T2D) is epigenetics that has primarily focused on DNA methylation and protein modifications. A missing link in this epigenetic framework is the modification(s) in mRNA and chromatin-associated regulatory RNAs (carRNAs) that have been shown to contribute to gene expression regulation at both posttranscriptional and transcriptional levels. Current data indicate altered expression of various regulators in metabolic tissues (e.g. human islets, adipose, liver, skeletal muscle) in obesity and type 2 diabetes; however, the significance of these alterations and the impact on mRNA and protein expression in real human tissues is virtually unknown. Consistent with the requirement of a RC2 mechanism, we will develop a comprehensive database of functionally important RNA modifications in selected human tissues. We seek to interrogate alterations in the modifications of RNA, specifically, the two most important modifications, N6-adenosine methylation (m6A) and pseudouridylation in key metabolic cell types that are relevant for type 2 diabetes and obesity. In this proposal, we will: 1) Interrogate the mRNA and chromatin- associated RNA modifications, m6A-sequencing and BID-ψ-sequencing at base resolution with stoichiometry information in key metabolic tissues from patients with T2D and obesity; 2) Perform m6A and ψ QTL studies in tissues from patients with T2D and obesity and validate the functional relevance of key mRNA and chromatin- associated RNA modifications in in vitro studies; 3) Interrogate comprehensive transcription and enhancer activity using ATAC-seq in the metabolic tissues from patients with T2D and obesity; 4) Perform eQTL studies using transcriptional activity data obtained from KAS-seq and RNA modification results on carRNAs in T2D and obese tissues, and perform validation in in vitro studies; and 5) Develop a large-scale resource database on mRNA and chromatin-associated RNA modifications and transcription activity with correlation of common genomic features for the larger scientific community. The success of this project will lay ground for the broader community to take advantage of these data and our analyses for future basic and translational investigations and therapeutic developments.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,972,780 )
2025	2025	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	8/22/2025	NON-COMPETING CONTINUATION	$1,972,780
														Subtotal = $1,972,780

Issue Date FY: 2024 ( Subtotal = $2,043,780 )
2024	2024	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	1	9/18/2024	NEW	$0
2024	2024	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	6/27/2024	NEW	$2,043,780
														Subtotal = $2,043,780

Grand Total All Awards = $4,016,560

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Epitranscriptomics in human obesity and type 2 diabetes

Award Number: RC2DK139552

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2024

PERIOD OF PERFORMANCE END DATE: 06/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer